Advertisements



Dynavax reports interim data for study of SD-101 in combination Merck"s Keytruda

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Merck Reports Positive Phase III Liver Cancer Data on Keytruda

Merck (MRK), announces first time results from the phase II study evaluating the use Keytruda in patients with advanced hepatocellular carcinoma (HCC), previously treated with sorafenib. Merck & Co., Inc. MRK announced data f.....»»

Category: personnelSource: nytJan 22nd, 2018

Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half. New study results released Monday continue to cemen.....»»

Category: europeSource: fortuneApr 16th, 2018

Merck Strong on Confirmatory Phase III Lung Cancer Study

Merck's (MRK) Keytruda in combination with Eli Lilly's Alimta and carboplatin meet dual primary endpoints in a confirmatory phase III study for the first-line treatment of lung cancer. Merck's MRK shares gained more th.....»»

Category: personnelSource: nytJan 17th, 2018

Roche Reports Positive Data from Tecentriq Combination Study

Roche reported positive data from a combination study of Tecentriq and Avastin in metas.....»»

Category: dealsSource: nytDec 11th, 2017

Roche Reports Tecentriq/Avastin Lung Cancer Study Data

Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer. Roche’s RHHBY member Genentech, annou.....»»

Category: personnelSource: nytDec 7th, 2017

Roche Reports Positive Data From Tecentriq Combination Study

Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin. .....»»

Category: dealsSource: nytNov 20th, 2017

One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings

Merck & Co., Inc. (NYSE: MRK)’s Keytruda returned better-than-expected results in the Keynote-189 lung study — a feat seen to lend a competitive edge over Bristol-Myers Squibb Co (NYSE: BMY). Latest Ratings for BMY Da.....»»

Category: blogSource: benzingaApr 17th, 2018

Dynavax provides durability response data for SD-101 with KEYTRUDA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 17th, 2018

Intercept Reports Phase III Sub-Study Liver Biopsy Data

Intercept (ICPT) announces data from the POISE biopsy sub-study which showed that treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patien.....»»

Category: worldSource: nytApr 16th, 2018

Gilead (GILD) Presents Encouraging Data on NASH Therapies

Gilead Sciences (GILD) announces encouraging data from a proof-of-concept study on experimental combination NASH therapies at The International Liver Congress 2018 in Paris. Gilead Sciences, Inc. GILD announced encouraging data from .....»»

Category: smallbizSource: nytApr 16th, 2018

Incyte Shares Fall After Cancer Drug Fails in Trial With Merck"s Keytruda

Incyte said its experimental cancer drug failed in a clinical trial that paired it with Merck’s Keytruda, striking a blow to combination therapies......»»

Category: smallbizSource: wsjApr 6th, 2018

Incyte"s stock plunges, Merck shares fall after disappointing study results of melanoma treatment

Shares of Incyte Corp. plunged 19% in premarket trade Friday, and Merck & Co. Inc.'s stock dropped 1.9%, after the companies said an external data monitoring comm.....»»

Category: topSource: marketwatchApr 6th, 2018

Incyte"s stock set for selloff, Merck shares drop after disappointing study results of melanoma treatment

Incyte Corp. and Merck & Co. Inc. said an external data monitoring committee (eDMC) determined that results from a phas.....»»

Category: topSource: marketwatchApr 6th, 2018

Aeglea Initiates Lung Cancer Combination Study With Keytruda

Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilargi.....»»

Category: worldSource: nytApr 3rd, 2018

Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress

− Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Myeloma Remains on Track; Top-Line Data Expected end of April 2018 –.....»»

Category: earningsSource: benzingaMar 15th, 2018

Portola Pharma (PTLA) Announces New Interim Data From Late-Stage Study Of AndexXa - Slideshow

Portola Pharma (PTLA) Announces New Interim Data From Late-Stage Study Of AndexXa - Slideshow.....»»

Category: topSource: seekingalphaMar 13th, 2018

Anthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - Slideshow

Anthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - Slideshow.....»»

Category: topSource: seekingalphaMar 13th, 2018

Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones

First Tazemetostat NDA Submission for Epithelioid Sarcoma Targeted for Fourth Quarter of 2018; Second Tazemetostat NDA Submission for Follicular Lymphoma Targeted for 2019 Multiple Phase 2 Study Data Readouts Planned in 2018 Confer.....»»

Category: earningsSource: benzingaMar 13th, 2018

Advaxis reports FDA clinical hold on combination study of axalimogene filolisbac

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 12th, 2018

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update

First patient enrolled in long term safety study in November 2017 Pivotal efficacy data for M207 published in Octobe.....»»

Category: earningsSource: benzingaMar 12th, 2018